



Justification Document for the Selection of a CoRAP Substance

Substance Name (public name): Perfluamine

EC Number: 206-420-2

CAS Number: 338-83-0

Authority: BE MSCA

Date: 22/03/2016

Note

This document has been prepared by the evaluating Member State given in the CoRAP update.

Contents

1	IDENTITY OF THE SUBSTANCE	3
1.1	Other identifiers of the substance	3
2	OVERVIEW OF OTHER PROCESSES / EU LEGISLATION	4
3	HAZARD INFORMATION (INCLUDING CLASSIFICATION)	5
3.1	Classification	5
3.1.1	Harmonised Classification in Annex VI of the CLP	5
3.1.2	Self classification	5
3.1.3	Proposal for Harmonised Classification in Annex VI of the CLP	5
4	INFORMATION ON (AGGREGATED) TONNAGE AND USES	6
4.1	Tonnage and registration status	6
4.2	Overview of uses	6
5.	JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE	8
5.1.	Legal basis for the proposal	8
5.2.	Selection criteria met (why the substance qualifies for being in CoRAP)	8
5.3	Initial grounds for concern to be clarified under Substance Evaluation	8
5.4	Preliminary indication of information that may need to be requested to clarify the concern	9
5.5	Potential follow-up and link to risk management	10

1 IDENTITY OF THE SUBSTANCE


1.1 Other identifiers of the substance

Table: Other Substance identifiers

EC name (public):	perfluamine
IUPAC name (public):	1,1,2,2,3,3,3-heptafluoro-N,N-bis(heptafluoro propyl)propan-1-amine
Index number in Annex VI of the CLP Regulation:	not listed
Molecular formula:	C ₉ F ₂₁ N
Molecular weight or molecular weight range:	521.07 g/mole
Synonyms:	

Type of substance Mono-constituent Multi-constituent UVCB

Structural formula:



Other relevant information about substance composition :

/

1.2 Similar substances/grouping possibilities

In the registration dossier the substance is included in a category approach with other perfluorinated substances, such as :

Perfluorohexane, CAS# 1064697-81-9

Perfluoroheptane, CAS# 1064698-16-3

Perfluorotributylamine, CAS# 1064698-37-8

Perfluoro-N-methylmorpholine, CAS# 382-28-5

Perfluoro-N-C1,3-alkyl morpholine, CAS# 1093615-61-2

Perfluoro-C6,8-furans, pyrans and acyclic ethers , CAS# 1064698-52-7

Read across data is included in the dossier for several endpoints in relation to physico-chemical properties, ecotoxicity en toxicity tests. The appropriateness of the read-across approach needs further analysis and seems to be not valid.

2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION

Table: Completed or ongoing processes

RMOA	<input type="checkbox"/> Risk Management Option Analysis (RMOA)	
REACH Processes	Evaluation	<input type="checkbox"/> Compliance check, Final decision
		<input type="checkbox"/> Testing proposal
		<input type="checkbox"/> CoRAP and Substance Evaluation
	Authorisation	<input type="checkbox"/> Candidate List
		<input type="checkbox"/> Annex XIV
Restriction	<input type="checkbox"/> Annex XVII ¹	
Harmonised C&L	<input type="checkbox"/> Annex VI (CLP) (see section 3.1)	
Processes under other EU legislation	<input type="checkbox"/> Plant Protection Products Regulation Regulation (EC) No 1107/2009	

¹ Please specify the relevant entry.

	<input type="checkbox"/> Biocidal Product Regulation Regulation (EU) 528/2012 and amendments
Previous legislation	<input type="checkbox"/> Dangerous substances Directive Directive 67/548/EEC (NONS)
	<input type="checkbox"/> Existing Substances Regulation Regulation 793/93/EEC (RAR/RRS)
(UNEP) Stockholm convention (POPs Protocol)	<input type="checkbox"/> Assessment
	<input type="checkbox"/> In relevant Annex
Other processes / EU legislation	<input type="checkbox"/> Other (provide further details below)

3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)

3.1 Classification

3.1.1 Harmonised Classification in Annex VI of the CLP

No harmonised classification.

3.1.2 Self classification

- In the registration:
None
- The following hazard classes are in addition notified among the aggregated self classifications in the C&L Inventory:

Acute Tox. 4	H302
Acute Tox. 3	H311

 Eye Irrit. 2, C \geq 10% H319

3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP

Currently no proposal for harmonised classification.

4 INFORMATION ON (AGGREGATED) TONNAGE AND USES²

Dissemination website was consulted on 28 May 2015.

4.1 Tonnage and registration status

Table: Tonnage and registration status

From ECHA dissemination site		
<input checked="" type="checkbox"/> Full registration(s) (Art. 10)	<input type="checkbox"/> Intermediate registration(s) (Art. 17 and/or 18)	
Tonnage band (as per dissemination site)		
<input type="checkbox"/> 1 - 10 tpa	<input type="checkbox"/> 10 - 100 tpa	<input checked="" type="checkbox"/> 100 - 1000 tpa
<input type="checkbox"/> 1000 - 10,000 tpa	<input type="checkbox"/> 10,000 - 100,000 tpa	<input type="checkbox"/> 100,000 - 1,000,000 tpa
<input type="checkbox"/> 1,000,000 - 10,000,000 tpa	<input type="checkbox"/> 10,000,000 - 100,000,000 tpa	<input type="checkbox"/> > 100,000,000 tpa
<input type="checkbox"/> <1 >+ tpa (e.g. 10+ ; 100+ ; 10,000+ tpa)		<input type="checkbox"/> Confidential

4.2 Overview of uses

Table: Uses

Part 1:

<input checked="" type="checkbox"/> Manufacture	<input checked="" type="checkbox"/> Formulation	<input checked="" type="checkbox"/> Industrial use	<input checked="" type="checkbox"/> Professional use	<input type="checkbox"/> Consumer use	<input type="checkbox"/> Article service life	<input type="checkbox"/> Closed system
---	---	--	--	---------------------------------------	---	--

Part 2:

	Use(s)
Uses as intermediate	Not mentioned in the registration dossier(s)
Formulation	PROC 5 - PROC 8b - PROC 9

² Please provide here the date when the dissemination site was accessed.

JUSTIFICATION DOCUMENT FOR THE SELECTION OF A CORAP SUBSTANCE

Uses at industrial sites	PROC 8a - PROC 8b - PROC 9 - PROC 1 - PROC 4 - PROC 15 - PROC 13
Uses by professional workers	PROC 1 - PROC 15 - PROC 8a - PROC 8b - PROC 9
Consumer Uses	Not mentioned in the registration dossier(s)
Article service life	Not mentioned in the registration dossier(s)

5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CoRAP SUBSTANCE

5.1. Legal basis for the proposal

- Article 44(2) (refined prioritisation criteria for substance evaluation)
 Article 45(5) (Member State priority)

5.2. Selection criteria met (why the substance qualifies for being in CoRAP)

- Fulfils criteria as CMR/ Suspected CMR
 Fulfils criteria as Sensitiser/ Suspected sensitiser
 Fulfils criteria as potential endocrine disrupter
 Fulfils criteria as PBT/vPvB / Suspected PBT/vPvB
 Fulfils criteria high (aggregated) tonnage (*tpa* > 1000)
 Fulfils exposure criteria
 Fulfils MS's (national) priorities

5.3 Initial grounds for concern to be clarified under Substance Evaluation

Hazard based concerns		
CMR <input type="checkbox"/> C <input type="checkbox"/> M <input type="checkbox"/> R	Suspected CMR ¹ <input type="checkbox"/> C <input type="checkbox"/> M <input type="checkbox"/> R	<input type="checkbox"/> Potential endocrine disruptor
<input type="checkbox"/> Sensitiser	<input type="checkbox"/> Suspected Sensitiser ³	
<input type="checkbox"/> PBT/vPvB	<input checked="" type="checkbox"/> Suspected PBT/vPvB ¹	<input type="checkbox"/> Other (please specify below)
Exposure/risk based concerns		
<input type="checkbox"/> Wide dispersive use	<input type="checkbox"/> Consumer use	<input type="checkbox"/> Exposure of sensitive populations
<input checked="" type="checkbox"/> Exposure of environment	<input type="checkbox"/> Exposure of workers	<input type="checkbox"/> Cumulative exposure
<input type="checkbox"/> High RCR	<input type="checkbox"/> High (aggregated) tonnage	<input type="checkbox"/> Other (please specify below)

³ CMR/Sensitiser: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory)

Suspected CMR/Suspected sensitiser: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/suspected sensitising properties (not classified according to CLP harmonized or registrant self-classification)

Suspected PBT: Potentially Persistent, Bioaccumulative and Toxic

This substance belongs to the class of perfluorinated compounds and a few members of this class of substances are already identified as PBT or vPvB substances. As indicated in the argumentation documents supporting the identification as a PBT or vPvB-substance (cfr. annex XV documents for PFOA, PFNA, PFDA), these perfluorinated compounds show specific physico-chemical properties which distinguish them clearly from other non-(per/poly)fluorinated organic compounds. Certainly with regard to the bioaccumulative character of these compounds the usual assessment techniques are not reliable and cannot be used to come to definitive conclusions for this substance.

In the registration data, an evaluation of the potential PBT/vPvB character of this substance is presented and it is concluded by the Registrant(s) that this substance does not meet the PBT criteria. However, after evaluation of the argumentation presented by the Registrant(s), one has to conclude that several statements and arguments are not correctly substantiated and are at least premature. In general the data presented are not sufficient to take away the PBT/vPvB concern.

For many endpoints read-across data are presented while the validity of this approach is not established. Further, it should be noted that the correctness of the current assessment of the distribution of the substance in the environment is doubtful and cannot be accepted in the present form. Besides, at the moment the bioaccumulation profile of this substance is assessed based on fat solubility characteristics while it is generally accepted that per- and polyfluorinated compounds bioaccumulate by protein binding processes.

For the various endpoints the following observations can be made:

Persistence

There is no indication of biodegradation or abiotic degradation based on the available information. In the absence of additional information, it is appropriate to consider this substance as very persistent. As a result substantial levels of the substance in a condensed state could arise in the environment over long periods of time.

Bioaccumulation

There are no bioaccumulation tests available on any species. It should be pointed out that perfluorinated compounds tend to bioaccumulate via protein binding processes and that these bioaccumulation processes cannot be modeled via log Kow-values. Certainly for air-breathing organisms bioaccumulation is a plausible process and should be explored.

Toxicity

For this substance only an acute daphnia magna test is available. In this test no effects were seen up to the water solubility. For terrestrial species no tests are available. Consequently, no definitive conclusion can be formulated regarding the ecotoxicological properties of this substance.

Overall, for the moment no conclusion can be drawn in relation to the fate and the distribution of the substance in the environment. Further the bioaccumulation potential, mainly in air-breathing organisms, remains unclear. Both aspects should be further examined in order to come to a reliable conclusion on the PBT/vPvB properties of this substance.

5.4 Preliminary indication of information that may need to be requested to clarify the concern

<input type="checkbox"/> Information on toxicological properties	<input checked="" type="checkbox"/> Information on physico-chemical properties
<input checked="" type="checkbox"/> Information on fate and behaviour	<input type="checkbox"/> Information on exposure
<input checked="" type="checkbox"/> Information on ecotoxicological properties	<input type="checkbox"/> Information on uses
<input type="checkbox"/> Information ED potential	<input type="checkbox"/> Other (provide further details below)
<p>Information that allows to assess in a reliable way the distribution of the substance between the various environmental compartments. Information that allows to assess the bioaccumulation potential.</p>	

5.5 Potential follow-up and link to risk management

<input type="checkbox"/> Harmonised C&L	<input type="checkbox"/> Restriction	<input checked="" type="checkbox"/> Authorisation	<input type="checkbox"/> Other (provide further details)
<p>Depending on the outcome of the evaluation any of the above mentioned risk management measures could be initiated if warranted.</p> <p>If concerns for PBT/vPvB properties are confirmed by additional testing, an identification as SVHC belongs to potential follow-up actions.</p>			